Abstract 17667: Quality of Life in Age- and Gender-Matched Patients with Preserved and Reduced Left Ventricular Ejection Fraction
Background: Although the prognosis of heart failure (HF) patients with preserved ejection fraction (HF-PEF) seems as grim as the prognosis of HF patients with reduced ejection fraction (HF-REF), little is known about the impact of HF-PEF on quality of life (QoL) compared to HF-REF patients.
Aim: To examine whether there are differences in QoL between patients with HF-REF and HF-PEF in a well defined HF population.
Methods: Data were analyzed from 158 patients with HF-PEF (LVEF ≥40%) (41% female; age 72 ± 10; LVEF 51 ± 8%) and 158 age- and gender-matched patients with HF-REF (LVEF <40%) (41% female; age 73 ± 10, LVEF 26 ± 7%). At hospitalization, all HF patients had a B-type Natriuretic Peptide-level (BNP) >100 pg/mL or N-terminal pro B-type Natriuretic Peptide-level (NT-proBNP) >400 pg/mL. QoL was assessed at 1 month after discharge of an initial HF hospitalization by Cantril's Ladder of Life, RAND-36 and the Minnesota Living with Heart Failure (MLwHF) questionnaire.
Results: QoL between patients with HF-PEF and HF-REF did not differ significantly according to Cantril's Ladder of Life (6.3 ± 1 vs. 6.3 ± 2, p=0.862), all dimensions of the RAND-36, and the total and both subscale scores of the MLwHF questionnaire (total 43 ± 22 vs. 43 ± 23, p= 0.911; physical functioning 21 ± 11 vs. 21 ± 11, p= 0.664; emotional functioning 8 ± 6 vs. 8 ± 6, p= 0.544). All HF patients reported low scores of QoL both on the general and disease specific QoL questionnaires. BNP and NT-proBNP levels were higher in the HF-REF patients compared to the HF-PEF patients (BNP median 488 vs. 368, p< 0.001; NT-proBNP median 3045 vs. 1999, p< 0.001). However, after adjusting the QoL scores for BNP and NT-proBNP an association between QoL and LVEF was not found.
Conclusion: HF, regardless of LVEF, has great impact on QoL. Results demonstrate that HF-PEF patients reported the same low QoL as HF-REF patients. Interventions to improve outcomes, including QoL, need to be targeted at all HF patients regardless their EF.
- © 2010 by American Heart Association, Inc.